
Commentary|Videos|August 12, 2024
Significance of Newly Approved IPX203 for Parkinson Disease
In this opening segment, Hauser and Fernandez discussed the FDA approval of IPX203, a new long-acting levodopa formulation for Parkinson disease, highlighting its significance in improving treatment options and patient compliance.
Advertisement
Advertisement
Earlier this month, the FDA approved Amneal Pharmaceuticals’ investigational agent IPX203, an oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules, as a treatment for patients with Parkinson disease (PD). Marketed as Crexont, the therapy is an oral formulation CD/LD which includes immediate-release granules as well as extended-release pellets. In its announcement, Amneal noted it expects the oral treatment to be available to patients in the United States in September 2024.
Related to this article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.

The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.

Mitzi Joi Williams, MD, is joined by Temitope Adeyey, MD, and Chantale Branson, MD, to discuss headache and facial pain conditions beyond migraine.

William Roth, MD, assistant professor of neurology at the University of Chicago, discusses the role of the gut microbiome in stroke risk and recovery and emerging strategies to modify it in the acute and preventive settings.

Three randomized trials pooled in a new systematic review found that thrombectomy did not improve 90-day functional outcomes after medium or distal vessel occlusion stroke, while increasing bleeding risk.

In a phase 2a trial presented at CTAD 2026, neflamapimod kept plasma NfL stable in nonfluent variant primary progressive aphasia over 24 weeks.

Brian Lin, PhD, senior director of research at the Muscular Dystrophy Association (MDA), discussed the sessions he is most excited about at the 2027 MDA Clinical and Scientific Conference.
Advertisement
Advertisement

